Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects

Exclusion Criteria

• •Centers for Disease Control Medical Eligibility for Contraceptive use category 3 or 4 for contraceptive usage
• •Currently pregnant
• •Less than 6 months postpartum, less than 6 weeks abortion, not breast/chest feeding (cessation of lactation at least 6 weeks prior to enrollment)
• •Undiagnosed abnormal uterine bleeding pre-dating placement of contraceptive implant
• •Bleeding dyscrasia
• •Anticoagulation use
• •Active cervicitis
• •Allergy to Tranexamic Acid
• •Known renal insufficiency
• •History of venous thromboembolism
• •Current or past breast or uterine malignancy
• •Concurrent use of P450 pathway inducing drug
• •Implant is due to be switched out in 2 months or less from enrollment
• •Routine or chronic use of non-steroidal anti-inflammatory drugs (NSAIDs once daily or \>= 14 days per month)
• •Currently using oral contraceptives in addition to implant (to be eligible, needs to have 4-6 week washout period)
• •Prior pregnancy occurred while Nexplanon/Implanon was in place
• •Chronic use of Cannabidiol, THC, or marijuana (\>3 times per week) (patients could have used Cannabidiol, THC, or marijuana chronically in the past, but must have a washout time period of no use for at least one month prior to the study)
• •Chronic use of cigarettes (\>1 cigarette per week) (patients could have used cigarettes chronically in the past, but must have a washout time period of no use for at least six months prior to the study)